Monitor for future clinical trial updates on SAB-142, especially from the ongoing Phase 2b SAFEGUARD trial in type 1 diabetes. The capital raise extends the company's runway but increases share count significantly — watch for any changes in burn rate or development timelines.
Price Chart
Executive Summary
SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 per warrant, raising approximately $85 million in gross proceeds. The company plans to use the funds to advance its lead candidate, SAB-142, through clinical trials for type 1 diabetes and for general corporate purposes. An additional 3,311,688-share over-allotment option remains open for 30 days.
Key Financial Metrics
Key Facts
- SAB Biotherapeutics raised $85 million in gross proceeds through a public offering.
- Offering included 19,324,677 common shares at $3.85 and pre-funded warrants for 2,753,246 shares at $3.8499.
- Proceeds will fund clinical development of SAB-142 for type 1 diabetes, manufacturing, regulatory activities, and general corporate use.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Jefferies, UBS, Citigroup, and Barclays acted as joint book-runners.
Financial Impact
$85 million gross proceeds, with potential for additional $12.7 million if over-allotment is exercised (3,311,688 shares × $3.85)
Risk Factors
- Significant shareholder dilution from issuance of over 22 million shares and warrants.
- Clinical-stage risk: SAB-142 may fail in trials despite funding, leading to valuation decline.
- Execution risk in advancing manufacturing and regulatory plans with new capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $2.98 (−23.59%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $2.98 (−17.22%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $2.98 (+17.68%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $2.98 (−20.53%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $2.98 (+21.16%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $2.98 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access